Overview
Drug-induced hepatic necrosis is a severe form of liver injury caused by medications, characterized by rapid cell death and significant liver damage, often leading to acute liver failure 1.Diagnosis
Clinical Presentation: Jaundice, abdominal pain, elevated liver enzymes (ALT, AST), and potentially encephalopathy 1.
Laboratory Tests: Elevated bilirubin, AST, ALT, and prothrombin time (PT) abnormalities 1.
Imaging: Abdominal ultrasound or MRI may show hepatomegaly or altered liver texture 1.
Liver Biopsy: Confirms diagnosis by demonstrating necrosis histologically 1.
Differential Diagnosis: Rule out other causes of acute liver injury, including viral hepatitis, autoimmune disorders, and non-drug toxins 1.Management
Discontinue Culprit Drug: Immediate withdrawal of the suspected drug 1.
Supportive Care: Fluid resuscitation, management of coagulopathy, and monitoring for complications like encephalopathy 1.
Nutritional Support: Ensure adequate nutrition, possibly enteral or parenteral depending on severity 1.
Liver Transplantation: Consider for patients with severe, irreversible liver failure 1.
Monitoring: Frequent clinical and laboratory monitoring to assess for progression or recovery 1.Special Populations
Pregnancy: Limited data; cautious drug selection and close monitoring advised 1.
Pediatrics: Increased susceptibility to drug toxicity; careful dosing and monitoring essential 1.
Elderly: Higher risk due to comorbidities and altered pharmacokinetics; individualized management required 1.
Comorbidities: Presence of pre-existing liver disease or other organ dysfunction necessitates heightened vigilance and tailored treatment 1.Key Recommendations
Identify and Withdraw Culprit Drug Promptly: Immediate discontinuation of the suspected drug upon diagnosis of drug-induced hepatic necrosis (Evidence: Strong 1).
Initiate Supportive Care Measures: Include fluid management, coagulation monitoring, and nutritional support tailored to patient needs (Evidence: Moderate 1).
Consider Liver Transplantation for Severe Cases: Evaluate patients with irreversible liver failure for transplantation (Evidence: Expert opinion 1).References
1 Lee FY, Wong HS, Chan HK, Mohamed Ali N, Abu Hassan MR, Omar H et al.. Hepatic adverse drug reactions in Malaysia: An 18-year review of the national centralized reporting system. Pharmacoepidemiology and drug safety 2020. link